69 - Boehringer Ingelheim invests €100 million on its Lyon-Jonage site

After an initial investment of €200 million in July 2018, the German pharmaceutical group is adding €100 million for its Lyon-Jonage plant, specializing in the production of veterinary vaccines, which will be operational in 2023. The site still under construction will be located on manufacture of vaccines against foot-and-mouth disease and bluetongue. The future unit will also increase its storage capacity for Boehringer Ingelheim's antigen banks.

https://www.industriepharma.fr/boehringer-ingelheim-injecte-100-m-supplementaires-sur-son-site-de-lyon-jonage,121692